Civitas Therapeutics Announces Positive Phase 2b Results For CVT-301, Inhaled Levodopa For The Treatment Of Parkinson’s Disease
Published: Apr 28, 2014
CHELSEA, Mass.--(BUSINESS WIRE)--Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa). Study results from Phase 2 studies will be presented at the 66th Annual American Academy of Neurology Meeting on April 29, 2014 at 2:30pm ET in Philadelphia, PA.
Help employers find you! Check out all the jobs and post your resume.